The present study aimed to demonstrate whether miR-155 enables CD34+ CML cells to escape from the growth-inhibitory effects of TGF-β1 and bone morphogenetic protein (BMP) signaling. The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.